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OBJECTIVE: To estimate the long-term beneﬁts of
chemopreventive tamoxifen and mammography screen-
ing in women who are healthy but at high risk of devel-
oping breast cancer. Long-term beneﬁts were deﬁned in
terms of life expectancy (LE) gains achieved through 
addition of chemopreventive tamoxifen (5-year therapy)
to routine mammography screening.
METHOD: A Markov process with time-and-
state-dependent transition probabilities was developed.
Two hypothetical cohorts of high-risk women were 
initiated at age forty and were followed over their lifetime.
The ﬁrst cohort consumed tamoxifen and underwent
routine mammography screening as per recommendations
of the American Cancer Society (ACS). The second cohort
(control cohort) did not consume tamoxifen and under-
went mammography screening at rates observed in general
population settings (these rates are much lower than the
ones recommended by the ACS). Tamoxifen intervention
was modeled based on the 5-year Breast Cancer Preven-
tion Trial results. Data from published analyses, which
investigated effects of mammography screening on breast
cancer mortality, was used to model mammography
screening intervention. Mortality data were obtained from
life tables and other published sources.
RESULTS: Tamoxifen coupled with routine mammogra-
phy screening prolonged the average survival of cohort
members who started consuming the drug at age of forty
by 86.14 days as compared to the control group. One-way
sensitivity analysis was performed to evaluate the poten-
tial impact of each assumption on average cohort survival.
Sensitivity analysis involved varying intervention-related
effectiveness parameters, rates of intervention-related
adverse events, compliance with intervention, and mor-
tality rates associated with different health states in the
model. For all variations, tamoxifen plus routine mam-
mography screening group had higher average survival
than the control group.
CONCLUSION: The model was found to be robust to
sensitivity analysis and hence tamoxifen plus routine
mammography screening can be expected to increase 
survival among women who are at higher risk of 
breast cancer.
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AN INTERIM COST AND OUTCOME
COMPARISON ALONGSIDE A PROSPECTIVE
RANDOMIZED CLINICAL TRIAL COMPARING
EARLY INTENSIFICATION WITH BONE
MARROW TRANSPLANTATION (BMT) TO
CONVENTIONAL DOSE CHEMOTHERAPY FOR
PREVIOUSLY UNTREATED PATIENTS WITH
AGGRESSIVE NON-HODGKIN’S LYMPHOMA
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OBJECTIVES: To identify and compare the costs 
and outcomes associated with early intensiﬁcation with
bone marrow transplantation versus conventional dose
chemotherapy for previously untreated patients with
aggressive non-Hodgkin’s lymphoma at high risk for
relapse.
METHODS: Costs and patient responses (outcomes)
were evaluated for the ﬁrst 84 patients in this ongoing
prospective randomized clinical trial. Data were compiled
from November 1995 until May 2001. Patient outcomes
were retrieved from the institutional Protocol Data 
Management System and costs were retrieved from 
institutional ﬁnancial and administrative databases.
Direct costs included hospital, clinic, pharmacy, and
physician costs. Pearson chi square was used to analyze
the association between costs and treatment group.
RESULTS: Forty-four patients received conventional 
dose chemotherapy and 40 patients received BMT. The 
average cost of therapy per patient for conventional dose
chemotherapy was $61,515 (range $5,360 to $186,684)
and the average cost per patient for BMT was $133,365
(range $11,868 to $431,248). Outcomes were categorized
as complete response (n = 36), partial response (n = 35),
and other (incomplete to date n = 13). Costs were 
categorized as low (<$45,000), medium ($45,000–
$80,999), medium high ($81,000–$125,999), and high
(>$126,000). In the conventional dose chemotherapy
group 61.1% of patients had a complete response and
38.9% of patients in the BMT group had a complete
response. Costs for conventional dose chemotherapy
patients were in the low to medium cost groups, and costs
for BMT patients were in the medium-high to high cost
groups (chi square = 29.422, d.f. = 3, p < 0.001).
CONCLUSIONS: Overall, higher costs were observed in
the BMT group, and more complete responses were
observed in the conventional dose chemotherapy group.
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OBJECTIVES: To evaluate infectious disease outcomes
and cost of care for lymphoma and myeloma patients
admitted for infectious complications. To evaluate a 
Palm handheld as a tool for prospective data collection
utilizing Pendragon Forms software.
METHODS: Patients admitted to the Lymphoma/
Myeloma service receiving anti-infective therapy for
infectious diseases were followed. Targeted outcomes
were collected prospectively during hospitalization and
included length of hospitalization (days), adverse events
attributed to the anti-infective, febrile days (≥38.3°C),
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resolution of signs/symptoms, and survival. Financial
data were collected for the time of hospitalization.
RESULTS: Eleven patients have been enrolled. The
average age of the patients is 57 years (range 40–80). The
majority (64%) of the patients were female and 55% of
the patients had lymphoma. The infection was microbio-
logically documented in 27%, clinically documented in
46%, and twenty-seven percent of patients had a fever 
of unknown origin. The average length of hospitaliza-
tion was 9 days (range 3–27). One patient had an adverse
event due to an anti-infective and included chills and
rigors with amphotericin-B lipid complex. The average
number of febrile days was 3 (range 1–8). Every patient
except one had resolution of signs and symptoms of 
the infection. One patient died due to a viral pneumonia.
The anti-infective utilized most frequently was imipenem/
cilastatin. The average cost of hospitalization per patient
was $22,438 (range $5,222.60–$53,398.95). The average
cost of pharmaceuticals per patient was $6,947.50 (range
$2,929.81–$18,642.82).
CONCLUSIONS: Infectious complications in cancer
patients can produce morbidity and mortality as well 
as be costly. Infectious disease outcomes can easily be 
collected utilizing a Palm handheld.
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COMPARED TO OTHER COMBINATION
THERAPIES IN GERMANY
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OBJECTIVES: Gemcitabine/Cisplatin (Gem/Cis) is a
standard regime commonly used in the treatment of 
non-small cell lung cancer. This study uses currently 
available clinical trial data to evaluate the cost implica-
tions of Gem/Cis versus other combination regimes in
Germany.
METHODS: Two published randomised controlled clin-
ical trials were used for this retrospective cost analysis to
evaluate and compare the cost of platinum-based combi-
nation regimes. Comella et al. (2000) compared, among
others, Gem/Cis versus Vinorelbine/Cisplatin (Vin/Cis)
and Schiller et al. (2000) compares Gem/Cis with 
Paclitaxel/Cisplatin (Pac/Cis), Paclitaxel/Carboplatin
(Pac/Carbo) and Docetaxel/Cisplatin (Doc/Cis). Equal
efﬁcacy was assumed for the analysis. Resource use and
unit costs associated with both treatment and toxicity
management were collected from the perspective of a
German sickness fund. Only direct cost (acquisition 
and administration of chemotherapy, hospitalisation and
other medical resource use) were considered.
RESULTS: Based on the Comella et al. (2000) clinical
trial, Gem/Cis was associated with lower overall costs
compared to Vin/Cis (€7638 vs. €8143). The higher
acquisition cost of Gem/Cis was more than compensated
by lower drug administration cost (€798 vs. €1278) and
fewer adverse events resulting in fewer hospitalisations
(€1633 vs. €2680). Based on the Schiller et al. (2000),
Gem/Cis was associated with the lowest overall costs 
of all ﬁrst-line treatment arms, Pac/Carbo and Pac/Cis
(€8.418 vs. €12.268 and €11.050). Even though the drug
acquisition cost of Gem/Cis was lower than Doc/Cis,
higher administration cost lead to slightly higher total
cost of Gem/Cis compared to Doc/Cis (€8418 vs. €8331).
CONCLUSIONS: From the perspective of German 
sickness funds, Gem/Cis as ﬁrst line treatment offers cost
advantages over Pac/Cis and Pac/Carbo in the treatment
of non-small cell lung cancer. Further research is 
necessary to validate these ﬁndings in a setting outside of
clinical trials.
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OBJECTIVES: Data on costs of care and typical care
paths for patients with malignant lymphomas in Germany
are scarce. The aims of this prospective health economic
survey are to identify typical clinical pathways and assess
the costs and clinical beneﬁts of different treatment 
settings and modalities for patients with newly diagnosed
malignant lymphomas.
METHODS: The recruitment of patients for this project
started in 2000 and will be continued through 2003 in
the Cologne and Saarland regions, Germany. Data on
resource consumption and outcomes are collected
prospectively by means of a patient book and a health
economic questionnaire. For the cohort of the one-year
pilot phase, hospital costs and costs of chemotherapy 
for the ﬁrst 6 months since initial diagnosis were 
calculated.
RESULTS: 192 patients have been recruited during 
the pilot phase. Of these, 22 (11,5%) were diagnosed
with Hodgkin’s disease (HD), 111 (57,8%) with non-
Hodgkin’s lymphoma (NHL), 36 (18,8%) with chronic
lymphatic leukemia (CLL) and 18 (9,4%) with multiple
myeloma (MM) (5 = 2,6% undeﬁned). The treatment
setting was as follows: 72 (43,6%) of the patients were
treated in an outpatient setting, 37 (22,4%) in an 
inpatient setting and 56 (33,9%) in a combined inpatient 
and outpatient setting. 54 (33,5%) patients were treated
